Veradermics, Incorporated
MANE
$98.86
-$4.98-4.79%
NYSE
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Net Income | 13.70% | -24.65% | -26.17% | ||
| Total Depreciation and Amortization | -- | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -27.64% | 608.90% | -33.81% | ||
| Change in Net Operating Assets | 1,814.74% | 109.65% | 75.07% | ||
| Cash from Operations | 31.55% | 10.41% | -17.47% | ||
| Capital Expenditure | -- | -- | 100.00% | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -173.71% | 7.72% | 47.05% | ||
| Cash from Investing | -173.73% | 7.72% | 47.11% | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | 54.05% | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -100.00% | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | 64.50% | 79.99% | -98.47% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 2.92% | 810.51% | -15.50% | ||